FN3 Scaffold Proteins for High-Affinity Binding with Reduced Size
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic proteins, such as monoclonal antibodies, face limitations in terms of size, stability, and expression efficiency, and there is a need for alternative scaffold proteins that can bind to cellular targets with high affinity and specificity while offering improved biophysical properties.
Innovation Solution
Development of a protein scaffold based on a consensus sequence of fibronectin type III (FN3) domains, which includes altering specific loop regions to enhance binding capabilities and stability, allowing for the creation of libraries and specific binders that can be expressed in both prokaryotic and eukaryotic hosts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used as therapeutic proteins, then high affinity and specificity for target molecules are achieved, but the size is large and expression efficiency is limited
Solution Approach 1:
The patent extracts only the essential binding function from full monoclonal antibodies by using small protein scaffolds (20-50 kDa) that contain minimal structural elements required for target recognition. These scaffolds lack the complex constant regions and heavy chains of full antibodies, achieving binding functionality with significantly reduced molecular weight
Solution Approach 2:
The invention focuses binding specificity to localized loop regions (CDR-like regions) of the scaffold protein rather than requiring the entire antibody structure. By engineering hypervariable loops to provide target recognition while maintaining a stable core scaffold, the patent achieves high affinity binding with minimal protein mass
2Reliability
If traditional antibody structures are used, then binding functionality is achieved, but stability and solubility are insufficient
Solution Approach 1:
The patent systematically optimizes amino acid parameters within the scaffold structure, including increasing proline content in beta-turn regions to stabilize loops, optimizing charge distribution to enhance solubility, and engineering disulfide bridges to reinforce structural stability. These parameter optimizations enable the small scaffold to achieve thermal stability comparable to or exceeding full antibodies
Solution Approach 2:
The invention creates a composite structure combining a highly stable beta-sheet core scaffold with engineered hypervariable loops for binding. This composite architecture integrates the stability of the folded core domain with the specificity of optimized surface loops, achieving both structural robustness and binding functionality
3Reliability
If protein scaffolds are engineered to bind specific targets, then binding capability is improved, but the complexity of library construction and screening increases
Solution Approach 1:
The patent divides the binding function into separate modular elements: a stable core scaffold providing structural framework and engineered loop regions providing target recognition. This segmentation allows independent optimization of stability (core) and binding (loops), simplifying library construction by focusing mutagenesis on specific loop regions rather than the entire protein
Solution Approach 2:
The invention creates a universal scaffold platform that can be applied to generate binders against multiple different targets. The conserved core structure serves as a universal foundation that can be paired with various engineered loops to recognize diverse targets, enabling a single scaffold design to serve multiple therapeutic indications
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG bassed on the consensus sequence have been identified as useful for diagnostic and/or therapeutic applications.